gptkbp:instance_of
|
gptkb:Company
|
gptkbp:bfsLayer
|
4
|
gptkbp:bfsParent
|
gptkb:Im_Clone_Systems
|
gptkbp:acquired
|
gptkb:Eli_Lilly_and_Company
|
gptkbp:acquisition
|
gptkb:2008
$6.5 billion
|
gptkbp:approves
|
gptkb:FDA
|
gptkbp:business_model
|
biopharmaceuticals
|
gptkbp:ceo
|
M. Sean Mc Carthy
|
gptkbp:clinical_trial
|
ongoing
positive
multiple phases
Phase III
|
gptkbp:collaborations
|
ongoing
academic institutions
biotech firms
|
gptkbp:committee
|
established
|
gptkbp:economy
|
gptkb:Company
|
gptkbp:employees
|
approximately 300
|
gptkbp:financial_performance
|
strong
|
gptkbp:founded
|
gptkb:1984
gptkb:New_York
|
gptkbp:founder
|
David Sidransky
|
gptkbp:grants
|
received
|
gptkbp:headcount
|
gptkb:300
|
gptkbp:headquarters
|
gptkb:Borough
gptkb:New_York
|
gptkbp:healthcare
|
gptkb:2004
oncology
|
https://www.w3.org/2000/01/rdf-schema#label
|
Im Clone Systems, Inc.
|
gptkbp:industry
|
Pharmaceuticals
|
gptkbp:invention
|
multiple patents in oncology
|
gptkbp:investment
|
oncology
publicly traded
various institutional investors
R& D
|
gptkbp:language_of_instruction
|
diverse
|
gptkbp:location
|
gptkb:United_States
|
gptkbp:market
|
gptkb:Erbitux
|
gptkbp:market_cap
|
approximately $6 billion
|
gptkbp:marketing_strategy
|
focused on oncology
|
gptkbp:notable_achievement
|
FDA approval for Erbitux in 2004
|
gptkbp:notable_allies
|
pharmaceutical companies
|
gptkbp:part_of
|
Eli Lilly and Company group
|
gptkbp:partnership
|
research institutions
|
gptkbp:partnerships
|
various pharmaceutical companies
|
gptkbp:products
|
gptkb:Erbitux
ongoing
monoclonal antibodies
multiple candidates
|
gptkbp:research_and_development
|
significant investment
|
gptkbp:research_areas
|
oncology
|
gptkbp:research_focus
|
gptkb:healthcare_organization
EGFR inhibitors
|
gptkbp:revenue
|
approximately $1 billion
|
gptkbp:subsidiary
|
Im Clone Systems, LLC
|
gptkbp:symbol
|
IMCL
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
gptkbp:treatment
|
cancer therapies
|
gptkbp:type
|
gptkb:football_club
|
gptkbp:website
|
www.imclone.com
|